FeetMe, a medical device company based in Paris, France has raised € 9.4 million in Series A funding. The investment round was led by LBO France, with additional investment from existing investors Kurma Diagnostics, the fund Paris Saclay seed fund, Idinvest Partners, Seventure and SOSV. FeetMe is a leading provider of real-world wetting gait assessment and rehabilitation solutions.
Read more European Researchers Team Up with Pharma Companies to Develop Gait Detecting Sensor
The fundraising will enable acceleration of FeetMe commercial activities in clinical trials for pharmaceutical industry and healthcare services for hospitals and rehabilitation facilities worldwide, the company said in a press release.
FeetMe’s innovative technology combines a device with a series of pressure sensors, motion sensors, and learning algorithms that collect movement data, including gait and posture data, and send this information in real time to a paired mobile application called FeetMe Evaluation.
100 million people worldwide suffer from gait disorders. Gait disorders are often a forerunner and indicator of evolutive diseases and health status: multiple sclerosis, Parkinson disease, fragility among elderly, peripheral neuropathies and diabetic foot problems, the press release said.
Besides analyzing gait and posture parameters, FeetMe also offers rehabilitation programs through its platform FeetMe Rehabilitation. A real-time smartphone-based biofeedback solution, FeetMe Rehabilitation gives patients access to personalized rehabilitation exercises selected by their healthcare providers that they can perform at home.
“With its disruptive yet technically validated technology, FeetMe establishes itself as the global leader in long-term continuous mobility assessment, with the potential to improve diagnosis for the millions of patients each year who present with known and unknown walking difficulties. I believe that FeetMe, with its vast technology capabilities, has the ability to create the world's largest and highest quality gait pattern data set to create a variety of new digital biomarkers across disease areas,” said Philippe Chambon, Venture Partner at LBO France.
